You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)就ABRAXANE與BMS-Celgene達成和解協議
百濟神州(06160.HK)公佈,就抗腫瘤藥ABRAXANE(注射用紫杉醇(白蛋白結合型))與BMS -Celgene的仲裁,雙方已於8月1日簽署和解及終止協議。 雙方同意共同撤回仲裁,BMS-Celgene同意向公司轉讓其於2017年從公司收購的2,327.31萬股公司普通股,在每一情形下均須遵守協議的條款和條件,並滿足若幹交割條件。 根據協議,百濟神州對轉讓的股份沒有任何付款義務。此外,雙方同意將於2023年12月31日終止許可和供應協議及質量協議,但百濟神州有權繼續銷售瑞復美和維達莎的所有庫存,直至售罄或2024年12月31日止。 百濟神州於2017年與BMS-Celgene簽訂許可和供應協定,獲獨家授權在中國分銷及推廣BMS-Celgene的產品ABRAXANE、瑞復美及維達莎。惟中國國家藥監局於2020年3月宣佈,基於對BMS-Celgene位於美國的合同生產機構的核查,決定暫停在中國進口、銷售和使用ABRAXANE。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account